Loading…
Loading…
CNVCF (BioHarvest Sciences Inc.) is no longer actively trading.
This usually means the company was acquired and taken private, delisted from its exchange, or its ticker has been retired. Every price, valuation, dividend, and analyst figure on this page is frozen at the last available trading session and reads as historical reference — not a current-day signal.
CNVCF does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for CNVCF and 80,000+ other tickers.
See exactly how CNVCF's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for CNVCF and 80,000+ other tickers.
BioHarvest Sciences Inc., along with its subsidiaries, supplies a range of nutraceutical products and medical cannabis to customers both in Israel and globally. The company leverages an innovative plant cell growth technology that allows it to cultivate active secondary metabolites directly from cells, completely circumventing the need to grow the actual plant. BioHarvest is responsible for the entire process, from designing and developing to manufacturing and marketing its offerings. These include Vinia, a nutraceutical powder derived from red grapes, as well as its medical cannabis line. The firm's main operational base is located in Vancouver, Canada.
BioHarvest Sciences Inc (NASDAQ:BHST, FRA:8MV0) has reported its financial results for the fourth quarter and full year 2025, highlighting revenue growth, improved margins, and continued investment in its product and contract manufacturing businesses. The company recorded full-year revenue of $34.5 million, representing a 37% increase compared to 2024.
BioHarvest Sciences Inc (NASDAQ:BHST, FRA:8MV0) announced that it has completed the first stage of a multi-phase development program focused on a rare scent-producing plant used in the global fragrance industry. The work was carried out through the company's contract development and manufacturing organization (CDMO) division under an agreement signed about a year ago.
BioHarvest Sciences Inc (NASDAQ:BHST, FRA:8MV0) said its VINIA product has become the top-selling resveratrol polyphenol nutraceutical brand in the United States, citing company data, as it continues to expand its direct-to-consumer business. The biotechnology company attributed VINIA's market position to its clinically studied ability to support arterial dilation and blood flow, a mechanism it says can enhance oxygen and nutrient delivery throughout the body.
BioHarvest Sciences Inc (NASDAQ:BHST, FRA:8MV0) said on Thursday that it has appointed former Israeli health ministry chief Hezi Levy to the board effective immediately. David Tsur will step down from its board of directors after more than four years of service, the company said in a statement.
BioHarvest Sciences Inc (NASDAQ:BHST) said its first full year as a Nasdaq-listed company was marked by revenue growth, expanding operations, and balance sheet improvements, according to a shareholder letter released on Wednesday by CEO Ilan Sobel. In the letter, Sobel outlined operating and financial progress made in 2025 and described the company's position entering 2026.